Pliant Therapeutics, Inc. Common Stock
PLRX Real Time Price USDRecent trades of PLRX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by PLRX's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Antibodies binding to α7β1 integrin antibodies and compositions thereof Nov. 05, 2024
-
Patent Title: Integrin inhibitor and uses thereof Jun. 25, 2024
-
Patent Title: Substituted amino acids as integrin inhibitors Apr. 09, 2024
-
Patent Title: Amino acid compounds with unbranched linkers and methods of use Jan. 02, 2024
-
Patent Title: N-acyl amino acid compounds and methods of use Jun. 13, 2023
-
Patent Title: Amino acid compounds and methods of use Apr. 25, 2023
-
Patent Title: Amino acid compounds and methods of use Jan. 24, 2023
-
Patent Title: Dosage forms and regimens for amino acid compounds Aug. 23, 2022
-
Patent Title: Amino acid compounds with unbranched linkers and methods of use Jul. 26, 2022
-
Patent Title: Substituted amino acids as integrin inhibitors Nov. 23, 2021
-
Patent Title: Amino acid compounds and methods of use Oct. 06, 2020
-
Patent Title: Amino acid compounds and methods of use Jun. 30, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of PLRX in WallStreetBets Daily Discussion
Recent insights relating to PLRX
Recent picks made for PLRX stock on CNBC
ETFs with the largest estimated holdings in PLRX
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view PLRX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.